GlassScriptPhysician profile
Jason Thomas
NPI 1265979280
$3,068.98
in general payments reported to CMS, 2019-2025
40 companies · $391 in 2025
The $391 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $471 · 2022: $769 · 2023: $825 · 2024: $613 · 2025: $391.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,804 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,803.99 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $467.70 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $367.27 | 2022-2025 | |
| Lilly USA, LLC | $220.16 | 2021-2024 | Mounjaro, Jardiance, Zepbound |
| Teva Pharmaceuticals USA, INC. | $172.39 | 2021-2024 | Ajovy |
| Takeda Pharmaceuticals U.S.A., INC. | $160.92 | 2021-2025 | Trintellix |
| Amgen INC. | $156.47 | 2021-2025 | Otezla, Repatha, Krystexxa |
| Organon LLC | $155.20 | 2022 | |
| Glaxosmithkline, LLC. | $128.99 | 2022-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $125.98 | 2021-2025 | Airsupra, Farxiga |
| Pfizer INC. | $123.22 | 2021-2025 | |
| Ironshore Pharmaceuticals INC. | $62.08 | 2022-2023 | Jornay Pm |
| Janssen Pharmaceuticals, INC | $61.21 | 2021-2023 | Spravato |
| Gilead Sciences, INC. | $59.59 | 2022-2023 | |
| Currax Pharmaceuticals LLC | $56.23 | 2021-2023 | Nexletol, Contrave, Onzetra Xsail |
| Idorsia Pharmaceuticals US INC | $54.56 | 2022-2023 | Quviviq |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.